CQV petitioned the Board for post-grant review (PGR) of the patent, arguing that the challenged claims were obvious in view of prior art samples of Xirallic®, a trademarked product produced by Merck.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback